title: Tumour necrosis factor and endotoxin synergistically activate intestinal phospholipase A2 in mice. Role of endogenous platelet activating factor and effect of exogenous platelet activating factor.
abstract: Previous studies have shown that: (a) platelet activating factor induces shock and intestinal injury, (b) exogenous platelet activating factor stimulates synthesis of endogenous platelet activating factor, and (c) tumour necrosis factor alpha and endotoxin synergise to induce shock and bowel injury in animals. These last two effects are largely mediated by platelet activating factor forming phospholipase A2 A2, a key enzyme for platelet activating factor synthesis, was examined in mouse intestine. It was found that tumour necrosis factor alpha and endotoxin synergise to stimulate platelet activating factor forming phospholipase A2 activity in the intestine, as well as platelet activating factor production, and these effects were blocked by pretreatment with platelet activating factor antagonists, SRI-63-441 and WEB 2086. In addition, exogenous platelet activating factor stimulates intestinal phospholipase A2 activity. These results show that tumour necrosis factor alpha and lipopolysaccharide synergistically activate the phospholipase A2 that participates in platelet activating factor formation, and this activation is largely mediated by endogenous platelet activating factor. Furthermore, platelet activating factor itself increases phospholipase A2 activity, suggesting that platelet activating factor induces its own synthesis, probably by phospholipase A2 activation.
authors.affiliation: Department of Pathology, Children's Memorial Hospital, Chicago, IL 60614.
authors.forename: X
authors.initials: X
authors.lastname: Sun
authors.forename: M S
authors.initials: MS
authors.lastname: Caplan
authors.forename: W
authors.initials: W
authors.lastname: Hsueh
mesh_terms: D000818:Animals; D001381:Azepines / Q000494:pharmacology; D004357:Drug Synergism; D004731:Endotoxins / Q000494:pharmacology*; D004789:Enzyme Activation / Q000187:drug effects; D007422:Intestines / Q000187:drug effects* / Q000201:enzymology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology; D011806:Quinolinium Compounds / Q000494:pharmacology; D013268:Stimulation, Chemical; D014230:Triazoles / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D001381:Azepines; D004731:Endotoxins; D008070:Lipopolysaccharides; D010972:Platelet Activating Factor; D011806:Quinolinium Compounds; D014230:Triazoles; D014409:Tumor Necrosis Factor-alpha; C050531:SRI 63-441; C052518:WEB 2086; D010741:Phospholipases A; D054467:Phospholipases A2